• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiac Function and the Risk of Dementia (P5.212)
CONCLUSIONS: Cardiac function is associated with the risk of dementia and Alzheimer disease, independently of cardiovascular risk factors and stroke. These results suggest that subclinical cardiac dysfunction is an independent risk factor for dementia. Hence, the utility of echocardiography for screening purposes for dementia should be further investigated.Disclosure: Dr. de Bruijn has nothing to disclose. Dr. Leening has nothing to disclose. Dr. Franco has received research support from ErasmusAGE. Dr. Hofman has received personal compensation in an editorial capacity for the European Journal of Epidemiology. Dr. Koudstaa...
Source: Neurology - April 9, 2014 Category: Neurology Authors: de Bruijn, R., Leening, M., Franco, O., Hofman, A., Koudstaal, P., Ikram, M. Tags: Aging, Dementia, and Cognitive and Behavioral Neurology: Epidemiology Source Type: research

Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (P5.002)
CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lopes, R., Garcia, D., Wojdyla, D., Dorian, P., Alexander, J., Wallentin, L., Lanas, F., Hanna, M., Held, C., Granger, C. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research

Effect of Apixaban on All-Cause Mortality in Atrial Fibrillation: An Imputed Placebo Analysis (P5.003)
CONCLUSIONS: This imputed placebo analysis suggests that apixaban significantly reduces all-cause mortality by about one-third in patients with AF.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance in formatting the abstract to ensure compliance with AAN guidelines was provided by Stephanie Finucane of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr. McMurray has nothing to disclose. Dr. Hart has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc., and Bristol-Myers Squibb Co. Dr. Flaker has received personal c...
Source: Neurology - April 9, 2014 Category: Neurology Authors: McMurray, J., Hart, R., Flaker, G., Lopes, R., Wang, J., Hanna, M., Alexander, J., Granger, C., Wallentin, L. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research

Clinical Features of Mild Cognitive Impairment of the Cerebrovascular Type (MCI-CVD) (P3.200)
CONCLUSIONS: These findings suggest that: 1) CVD is a prominent cause/contributor to MCI in community-based populations, 2) premortem identification of MCI-CVD rests on history of CVD risk factors and brain imaging, 3) standard neurological/neuropsychological examination cannot distinguish MCI-CVD from MCI-AD.Study Supported by: NIH P30AG028383 & R01NS014189Disclosure: Dr. Jicha has received personal compensation for activities with Quintiles. Dr. Jicha has received research support from Alltech, Baxter, Eli Lilly & Co., Janssen, and Pfizer Inc. Dr. Hench has nothing to disclose. Dr. Moser has nothing to disclose. ...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Jicha, G., Hench, L., Moser, D., Abner, E. Tags: Aging, Dementia, and Cognitive and Behavioral Neurology: Clinical Aspects Source Type: research

Cerebral Ischemic Events Associated with Intravenous Thrombolytic Administration in International Joint Efficacy Comparison of Thrombolytics (INJECT) Trial (P7.124)
Conclusions: Most cerebral ischemic events occur in the immediate post-thrombolytic period and result in disproportionately low survival over 6 months.Disclosure: Dr. Tasneem has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Tasneem, N., Adil, M., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Issues in Acute Stroke Treatment Source Type: research

Antiplatelet Drugs Resumption After Antiplatelet-Related Intracerebral Hemorrhage In Chinese (P7.141)
CONCLUSION:Antiplatelet resumption after AICH was not associated with an increased risk of vascular death. In view of the high rate of ischemic vascular event among survivors of AICH, antiplatelet resumption should be considered, especially in survivors with lower risk of recurrent ICH.Disclosure: Dr. Teo has nothing to disclose. Dr. Lau has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Chang has nothing to disclose. Dr. Siu has nothing to disclose. Dr. Leung has nothing to disclose. Dr. Cheung has nothing to disclose. Dr. Ho has nothing to disclose. Dr. Chan has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Teo, K. C., Lau, G., Lee, R., Chang, R. S., Siu, D. C., Leung, G. K., Cheung, R., Ho, S. L., Chan, K. H. Tags: Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage Outcome and Mortality Source Type: research

Does the Magnitude of the Electrocardiogram QT Interval Dispersion Predict Stroke Outcome? (P7.154)
CONCLUSIONS: We were unable to demonstrate that QTd is useful in predicting clinical outcome at discharge in AIS.Disclosure: Dr. Lederman has nothing to disclose. Dr. Steinberg has nothing to disclose. Dr. Balucani has nothing to disclose. Dr. Philip has nothing to disclose. Dr. Lazar has nothing to disclose. Dr. Weedon has nothing to disclose. Dr. Mirchandani has nothing to disclose. Dr. Viticchi has nothing to disclose. Dr. Falsetti has nothing to disclose. Dr. Silvestrini has nothing to disclose. Dr. Gugger has nothing to disclose. Dr. Aharonoff has nothing to disclose. Dr. Piran has nothing to disclose. Dr. Adler has n...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lederman, Y., Steinberg, L., Balucani, C., Philip, C., Lazar, J., Weedon, J., Mirchandani, G., Viticchi, G., Falsetti, L., Silvestrini, M., Gugger, J., Aharonoff, D., Piran, P., Adler, Z., Levine, S. Tags: Cerebrovascular Disease and Interventional Neurology: Predictors of Outcome After Ischemic Stroke Source Type: research

Cocaine and Ischemic Stroke: Epidemiological and Clinical Characteristics (P5.111)
Conclusion: Cocaine associated IS is a common cause of stroke in young. Lacunar and cardioembolic strokes are more common in cocaine related IS patients and may suggest potential mechanisms contributing to IS related to cocaine abuse.Disclosure: Dr. Vaishnav has nothing to disclose. Dr. Remmel has received personal compensation for activities with Pfizer Inc. and Boehringer Ingelheim Pharmaceuticals Inc. Dr. Moore has nothing to disclose. Dr. Ziegler has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Vaishnav, A., Remmel, K., Moore, K., Ziegler, C. Tags: Cerebrovascular Disease and Interventional Neurology: Epidemiology Source Type: research

Dabigatran -The Future Of Cortical Venous Thrombosis Therapy -A Case Series Study (P6.025)
ConclusionsAs these cases demonstrate, Dabigatran appears be effective and safe in the treatment of single cortical venous sinus thrombosis . However large scale randomized controlled trials will be required to confirm its efficacy as a therapeutic modality .Disclosure: Dr. Mathew has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Sarma has nothing to disclose. Dr. Nadig has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mathew, T., Alexander, L., Sarma, G., Nadig, R. Tags: General Neurology VI Source Type: research

Troponin Elevation in Intra-arterial Stroke Intervention (P4.211)
CONCLUSIONS: Aggressive treatment may increase the risk of troponin elevation without increasing mortality in AIS patients. This finding is reassuring in view of continued interest in IA treatment of stroke in addition to tPA thrombolysis.Disclosure: Dr. Kumar has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Alawi has nothing to disclose. Dr. Michael has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Kumar, A., Mehta, S., Alawi, A., Michael, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research

Intervention Stroke Assessment Scale for Eligibility in Endovascular Therapy (ISAS-ET) (P4.213)
Conclusion:In conclusion, the ISAS scoring system might help with the assessment of patient qualification for further endovascular treatment. Further prospective studies are warranted.Disclosure: Dr. Haitham has nothing to disclose. Dr. Bashir has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Misthal has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Kirmani has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Haitham, D., Bashir, A., Hussain, M., Misthal, S., Moussavi, M., Kirmani, J. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research

Thrombolytic Outcomes for Acute Ischemic Stroke in Patients with Primary Brain Tumors in the United States (P4.220)
Conclusions: Thrombolytic therapy is an independent predictor of ICH in patients with primary brain tumors. Thrombolysis outcomes are less favorable in malignant brain tumors compared to benign tumors.Disclosure: Dr. Murthy has nothing to disclose. Dr. Moradiya has nothing to disclose. Dr. Shah has nothing to disclose. Dr. Shastri has nothing to disclose. Dr. Bershad has nothing to disclose. Dr. Suarez has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Murthy, S., Moradiya, Y., Shah, S., Shastri, A., Bershad, E., Suarez, J. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

Thrombolytic Treatment for Acute Ischemic Stroke Patients with History of Migraine Headaches (P4.223)
Conclusion: Patients with migraine headaches receiving IV rt-PA treatment for acute ischemic stroke appear to have a lower rates of death and disability most likely related to their decreased rates of intracerebral hemorrhage.Disclosure: Dr. Malik has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Nickles has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Malik, A., Adil, M., Chaudhry, S., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

Vitreous Hemorrhage as a Complication of IV-tPA Therapy in a Patient with Acute Stroke (P4.227)
CONCLUSIONS: To our knowledge, this is the first case report of vitreous hemorrhage following acute stroke therapy with IV-tPA. This underscores the risk of intraocular hemorrhage in patients with retinal neovascularization that could occur with other retinal vascular disorders such as diabetic retinopathy. The decision to proceed with IV-tPA in the presence of retinal neovascularization should be made on a case-by-case basis and further discussion with the patient.Disclosure: Dr. Shah has nothing to disclose. Dr. Verstraeten has nothing to disclose. Dr. Wright has nothing to disclose. Dr. Rana has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Shah, L., Verstraeten, T., Wright, D., Rana, S. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

Review of Cardiac Abnormalities with Hypercoagulable Testing in Ischemic Stroke Patients (P4.234)
CONCLUSIONS: We found no relationship between abnormal HT findings and RTLS among individuals with ischemic stroke. However, there may be an association between abnormal HT results and severe LVH that is worthy of further exploration. Previous literature has demonstrated an association between hypertension and hypercoagulability. Disclosure: Dr. Anderson has nothing to disclose. Dr. Shah has nothing to disclose. Dr. Drake has received personal compensation for activities with UCB Pharma as a speaker. Dr. Proytcheva has nothing to disclose. Dr. Coull has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Anderson, N., Shah, A., Drake, K., Proytcheva, M., Coull, B. Tags: Cerebrovascular Disease and Interventional Neurology: Cardiac Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16